Toan NL, Hang NT, Luu NK, VAN Mao C, VAN Ba N, Xuan NT, Cam TD, Yamamoto N, VAN Tong H, Son HA. Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer.
Anticancer Res 2019;
39:3727-3737. [PMID:
31262899 DOI:
10.21873/anticanres.13521]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM
This study aims to investigate whether the combination of oncolytic viruses with chemoradiotherapy or other therapies is a promising strategy for cancer treatment.
MATERIALS AND METHODS
The anticancer effects of measles virus (MeV) in combination with nimotuzumab in the treatment of laryngeal cancer were evaluated in vitro and in nude mice inoculated with Hep2 tumors. MTT assay and flow cytometry were used to examine cell death.
RESULTS
Laryngeal cancer cells treated with MeV+nimotuzumab combination had a significantly lower survival rate compared to those treated with MeV or nimotuzumab alone (p<0.0001). In an animal model bearing human laryngeal tumor, the treated group had a higher survival rate (60%) compared to a untreated group (20%) (p<0.05), and the survival rate of the group treated with MeV+nimotuzumab combination was higher compared to the groups received single treatment.
CONCLUSION
The MeV+nimotuzumab combination has greater anticancer activities in both laryngeal cancer cells and an animal model.
Collapse